Ocugen to Present at Retinal Vascular Disease Drug Development Summit

MALVERN, Pa., Feb. 17, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the Retinal Vascular Disease Drug Development Summit at the Hilton Boston Logan Airport in Boston, Mass. from February 21-23, 2023.

“I am very pleased that Dr. Upadhyay will share his expertise in this specific area of retinal disease research at the Retinal Vascular Disease Drug Development Summit,” said Dr. Shankar Musunuri, Chairman, CEO & Co-Founder of Ocugen. “Through the work Dr. Upadhyay and his team are doing, Ocugen could potentially provide a viable therapeutic option to the significant percentage of people living with diabetic macular edema (DME) that are non-responders to the current standard of care.”

Presentation: Developing a Novel Therapeutic to Potentially Treat DME Patients that are Non-Responsive to Anti-VEGF Therapy
Date: Thursday, February 23, 2023
Time: 1:30 p.m. ET

Ocugen is developing OCU200—a novel fusion protein consisting of two human proteins, tumstatin and transferrin—for treating severely sight-threatening diseases like DME, diabetic retinopathy, and wet age-related macular degeneration. Patients affected by these diseases share common symptoms, such as blurriness in vision and progressive vision loss as the disease progresses. The formation of fragile and leaky new blood vessels leads to fluid accumulation in and around the retina, causing damage to vision.

The Company is currently executing IND-enabling studies for OCU200 and plans to submit an IND application in the first quarter of 2023.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
IR@ocugen.com